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ABSTRACT 
 
Background. Emerging technologies now allow for mass spectrometry based profiling of up to 
thousands of small molecule metabolites (‘metabolomics’) in an increasing number of biosamples. 
While offering great promise for revealing insight into the pathogenesis of human disease, 
standard approaches have yet to be established for statistically analyzing increasingly complex, 
high-dimensional human metabolomics data in relation to clinical phenotypes including disease 
outcomes. To determine optimal statistical approaches for metabolomics analysis, we sought to 
formally compare traditional statistical as well as newer statistical learning methods across a 
range of metabolomics dataset types.  
Results. In simulated and experimental metabolomics data derived from large population-based 
human cohorts, we observed that with an increasing number of study subjects, univariate 
compared to multivariate methods resulted in a higher false discovery rate due to substantial 
correlations among metabolites. In scenarios wherein the number of assayed metabolites 
increases, as in the application of nontargeted versus targeted metabolomics measures, 
multivariate methods performed especially favorably across a range of statistical operating 
characteristics. In nontargeted metabolomics datasets that included thousands of metabolite 
measures, sparse multivariate models demonstrated greater selectivity and lower potential for 
spurious relationships.  
Conclusion. When the number of metabolites was similar to or exceeded the number of study 
subjects, as is common with nontargeted metabolomics analysis of relatively small sized cohorts, 
sparse multivariate models exhibited the most robust statistical power with more consistent 
results. These findings have important implications for the analysis of metabolomics studies of 
human disease. 
 
Keywords: metabolomics, statistical methods, univariate, multivariate  
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BACKGROUND 
 
Mass spectrometry based measurements of small molecule metabolites, also known as 
metabolomics, has emerged as a powerful tool for phenotyping biochemical variation in health 
and disease across organisms. Accordingly, there has been a rapidly growing interest in applying 
metabolomics to clinical studies of human disease traits.[1,2] Metabolomics technologies have 
recently advanced from the measure of approximately 200 distinct small molecules in a ‘targeted’ 
fashion to reproducible quantification of up to several thousand small molecules using 
‘nontargeted’ approaches. Such technical advances have emphasized the need to determine 
optimal methods for the statistical analysis of high-dimensional metabolomics data. Robust 
statistical methods are particularly needed to examine associations of metabolites detected in 
peripheral blood circulation with disease traits in humans; in this context, false discovery remains 
a key concern for clinical biomarker studies.[3-5] The statistical analysis challenges posed by 
human metabolomics data arise from multiple sources. For instance, metabolomics data collected 
from a given biospecimen represents metabolite variation at a particular point in time and in a 
particular context: whereas a portion of the variability reflects the relatively stable components of 
the organismal metabolome, another component reflects the dynamic portion of the metabolome 
that varies substantially over time and in response to a number of exposures. Such mixed 
structure can lead to a high degree of variation for a given metabolite level across individuals. 
Additionally, due to common pathways of enzymatic production or exposures of origin, 
metabolites can demonstrate a high degree of inter-correlation, and this inter-correlation may vary 
between individuals or subgroups depending on disease state, exposures, or other factors.  
 
Initial clinical studies involving targeted metabolomics approaches have used relatively 
conservative statistical approaches to analyzing up to 200 variables, such as Bonferroni 
correction of multiple t-tests or the false discovery rate (FDR).[6] Additionally methods of 
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accounting for multiple hypothesis testing have similarly assigned more or less conservative 
thresholds for defining statistical significance. In the absence of considering inter-correlations 
between individual metabolites at the outset, data analyses will tend to favor identifying 
metabolites from a singular biological pathway, with secondary or tertiary associations (potentially 
representing important orthogonal pathways) being forced to reach lower levels of statistical 
significance based on rank ordering alone. For this reason, traditional statistical approaches are 
believed to offer limited sensitivity for high-dimensional metabolomics analyses. Thus, several 
alternative methods have been proposed to more effectively select metabolites associated with a 
given outcome.[7-11] These methods have begun to surface from analyses of other molecular 
phenomics datasets,[9,10,12,13] although they may differ in structure relative to metabolomics 
datasets. Each statistical method has intrinsic strengths and weaknesses, and the extent to which 
they may be more or less suited for a given metabolomics analysis is not known but is likely to 
depend on number of metabolites assayed, sample size, and frequency or type of clinical 
outcome. Therefore, we sought to formally test currently available statistical methods across a 
range of dataset types. By simulating clinical studies to test different outcomes-based hypotheses 
and validating findings using real metabolomics data, we aimed to assess the suitability of 
statistical methods for the analysis of metabolomics data across a range of clinical data settings.  
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METHODS 
 
Development of Simulated Metabolomics Dataset  
We developed a series of simulated metabolomics datasets based on the characteristic data 
features seen in both experimental and human studies (small case-control as well as large cohort) 
using both targeted and nontargeted mass spectrometry methods. In particular, we designed the 
datasets to include the range of structural characteristics typically observed in human plasma 
metabolomics datasets. 
 
Structural features with respect to outcomes included: (i) binary outcomes in small-sized studies 
of up to 200 individuals with an outcome frequency of 50%, representing case-control studies with 
a 1:1 case/control ratio; (ii) binary outcomes in large-sized studies with an outcome frequency of 
20% in cohorts with >200 individuals, representing larger observational cohort studies; (iii) 
continuous outcomes measured in all patients. Structural features with respect to exposures 
included: (i) number of metabolites ranging from 200 (as is typical of a targeted method) to 2000 
(representative of an nontargeted method); (ii) metabolite values following a normal distribution, 
which is similar to what is commonly observed after a logarithmic or other transformation of the 
data; (iii) general positive correlation between metabolites, with pairwise correlations randomly 
distributed around a mean of +0.40; (iv) clustering within the data such that large groups of 
metabolites are highly correlated with each other representing biological pathways; and (iv) the 
number of "true positive" metabolites independently associated with the clinical outcome set to 
10, with varying effect sizes. A summary of the data structures is provided in Table 1 and an 
example correlation matrix induced by our simulation design is shown in Figure 1. 
 
Statistical Approaches for Analyzing Metabolomics Data 
 6 
 
For comparison of analyses, we applied the following statistical methods to the simulated 
metabolomics datasets: (1) univariate analyses with multiple testing correction using the 
Bonferroni or false discovery rate (FDR) approach;[6] (2) principal component regression 
(PCR);[14,15] (3) sparse partial least squares (SPLS);[8,10] (4) sparse partial least squares 
discriminant analysis (SPLSDA);[8,9] (5) random forests;[7] and (6) least absolute shrinkage and 
selection operator (LASSO).[11] Univariate analyses with multiple testing correction, including 
Bonferroni correction or the Benjamini-Hochberg correction for FDR, have been applied in a 
variety of predominantly targeted metabolomics studies previously.[16-18] The PCR approach, 
also applied in prior metabolomics studies, reduces the dimension of the total number of 
metabolite variables. PCR first reduces the dimensionality of the metabolite data, then uses the 
selected principal components in a regression model to predict the clinical outcome variable. 
Finally, variable importance measures are derived by reallocating the estimated regression 
coefficients to the metabolites that contributed to each of the chosen principal components. The 
PLS regression method maximizes the covariance between a matrix of metabolite variables and 
the outcome variable, where the outcome is typically a continuous variable; for categorical 
outcome variables, a variant called PLS discriminant analysis [PLSDA][19] may be applied. Either 
PLS or PLSDA serve to decompose metabolite and outcomes data into latent structures and aim 
to maximize the covariance between these latent structures. The random forests method employs 
a non-parametric ensemble approach to predicting an outcome from metabolomics data by 
identifying presumably non-linear patterns that may account for metabolite variation in relation to 
a particular outcome.[7] PCR, PLS, PLSDA, and random forests all suffer from a similar problem 
when trying to identify important metabolites: While they can rank order the metabolites in terms 
of importance, there is no obviously principled way to select a cutoff for which metabolites are 
‘significantly’ associated with the outcome. There exist ad hoc approaches to performing variable 
selection in some of these contexts;[20,21] however, there is no consensus on the appropriate 
manner for selecting important metabolites. Naïve approaches such as simply taking the top K 
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covariates to be significant can be applied, but their properties are not well understood and their 
performance will vary greatly across data sets depending on the true number of significant 
metabolites present. One way to overcome this issue is to use models that induce sparsity in their 
respective coefficients. Sparsity refers to the assumption that, adjusting for all measured 
metabolites, the number of metabolites that are truly associated with the clinical outcome (true 
positives) is far smaller than the overall number of metabolites. The most popular such approach 
in the field of statistics is LASSO,[11] a method that regresses a given outcome on all metabolite 
variables simultaneously and achieves parsimonious variable selection by applying a penalty to 
the magnitude of the regression coefficients. Because many statistical methods are unable to 
simultaneously model a number of metabolites which exceeds the number of study subjects, the 
assumption of sparsity allows for many more traditional methods to be extended to such high-
dimensional data. Notably, sparse extensions of approaches such as PLS and PLSDA, exist[7-
10] and are useful for their application in metabolomics. Sparse extensions of these methods 
provide automatic variable selection, which solves the aforementioned issue that these methods 
only allow for variable importance ranking. The FDR approach was implemented using the 
Benjamini-Hochberg procedure with a false discovery rate of 0.1. Parameters of multivariate 
approaches such as LASSO, SPLS, and SPLS-DA were selected using cross-validation. 
Variables were ranked based on the magnitude of the absolute value of the relevant regression 
coefficients for LASSO, SPLS, and PCR, while variable importance measures were used for 
random forests 
 
It is also important to clarify the distinction between variable selection and significance testing. 
Methods such as the LASSO or other sparse models do not perform significance testing in the 
traditional sense of controlling type I error or testing hypotheses. Rather, they simply identify a 
set of metabolites that are relatively important for predicting a given outcome. Thus, herein, we 
will compare approaches aimed at identifying metabolites of greatest interest, in relation to a given 
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outcome, wherein some approaches involve traditional hypothesis testing while others involve 
simply variable selection.  
 
To compare the performance between statistical methods in this regard, we evaluated the 
following metrics: (i) probability of identifying a true positive metabolite through variable 
selection/significance testing as function of the true effect size (among those methods which allow 
for such identification); (ii) probability of identifying a true positive metabolite as a "top 10" 
metabolite as a function of effect size; (iii) average number of false positive metabolites identified 
by variable selection/significance testing; (iv) positive predictive value (PPV), the probability that 
a metabolite identified through variable selection/significance testing is truly related to the clinical 
outcome; (v) negative predictive value (NPV), the probability that a metabolite not identified is 
truly unrelated to the clinical outcome. These metrics were evaluated separately for continuous 
and binary outcomes, with all analyses performed using Rv3.2.3 (R Development Core Team, 
Vienna, Austria). To visualize the relatedness of metabolites, Spearman correlation coefficients 
were estimated for all pairs of metabolites and correlations above ≥0.65 were isolated, with 
clusters of these correlations visualized using a D3 visualization framework 
(https://github.com/d3/d3-force); within this visualization, metabolites associated with sex and age 
via the Bonferroni, FDR, SPLS, and LASSO methods were highlighted. 
 
Experimental Human Metabolomics Data 
As part of the community-based Framingham Heart Study, the offspring cohort participants 
underwent a standardized evaluation that included fasting blood sample collection at their eighth 
examination in 2002-2005, as previously described.[22] All participants provided informed 
consent and all protocols were approved by the institutional review boards at Boston University 
Medical Center, Brigham and Women’s Hospital, and the University of California, San Diego. LC-
MS based metabolomics analysis was performed on all available N=2895 plasma samples, 
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according to previously described protocols.[23] In brief, plasma samples were prepared and 
analyzed using a Thermo Vanquish UPLC coupled to a high resolution Thermo QExactive orbitrap 
mass spectrometer. Metabolites were isolated from plasma using protein precipitation with 
organic solvent followed by solid phase extraction. Extracted metabolites underwent 
chromatographic separation using reverse phase chromatography whereby samples were loaded 
onto a Phenomenex Kinetex C18 (1.7um, 2.1x100mm) column and eluted using a 7 minute linear 
gradient starting with water : acetonitrile : acetic acid (70:30:0.1) and ending with acetonitrile : 
isopropanol : acetic acid (50:50:0.02). LC was coupled to a high resolution Orbitrap mass analyzer 
with electrospray ionization operating in negative ion mode, with full scan data acquisition across 
a mass range of 225 to 650 m/z. Thermo .raw data files were converted to 32-bit centroid .mzXML 
using Msconvert (Proteowizard software suite), and resulting .mzXML files were analyzed using 
Mzmine 2.21, as described.[23] To eliminate redundant and non-metabolic chromatographic 
features, we applied the following filters: naturally occurring 13C isotopes were consolidated under 
the monoisotopic peak; common adducts (i.e. H+, Na+, NH4+, and K+ for positive mode and H-, Cl-
, and acetate for negative mode) were consolidated with the most abundant species being 
reported; multiple charge states were consolidated with the singly charged state with the most 
abundant being reported; and, common ESI in-source fragments (e.g. loss of water) were 
removed. In addition, all chromatographic features present in a sample blank subjected to the 
entire sample preparation protocol (with the exception of water being used instead of plasma) 
were removed. Finally, all remaining chromatographic features were manually inspected for 
quality in peak shape, retention time consistency, and signal to noise ratio, with features exhibiting 
sub-par characteristics subsequently removed. Known compounds that are typically observed in 
human plasma when applying this method are listed in Table S1. 
 
From plasma collected from N=2895 participants, a total of 1933 distinct metabolite species were 
measured with a non-missing value recorded for every participant. We log transformed and 
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standardized all metabolites to have mean 0 and standard deviation 1 due to the expectedly right-
skewed nature of the data. Using the same statistical analytical methods described above, we 
conducted analyses to identify distinct metabolites demonstrating significant associations with 
age and sex. These phenotypes were specifically selected given both are basic factors available 
in almost all biomarker analyses, and they allow for analysis of a continuous and binary outcome, 
respectively.  
 
RESULTS  
 
Statistical Analyses of Simulated Metabolomics Data 
Metabolomics studies of human samples can vary substantially by sample size, the number of 
metabolites assayed, and the type and frequency of a clinical outcome of interest, with each of 
these factors potentially influencing statistical analysis results. To evaluate statistical methods for 
handling of a variety of datasets, metabolomics data were simulated for clinical studies of varying 
number of study subjects, number of metabolites, and outcome type (continuous vs binary).  A 
total of six traditional statistical (Bonferroni, FDR, and PCR) and statistical learning (LASSO, 
SPLS, and random forest) methods were used to analyze 1000 simulated metabolomics datasets 
(Figures 2-3), with each evaluated for the likelihood of a metabolite being correctly identified as 
one of the top 10 most important metabolites with respect to a given outcome. For a simulated 
continuous outcome (Figure 2), all approaches performed similarly well, with the exception of 
scenarios with a large number of metabolites (M=2000) or a small number of subjects (N=200). 
At these extremes, multivariate approaches based on sparsity, LASSO and SPLS, were found to 
outperform univariate approaches. In the case of a binary outcome (Figure 3), optimal statistical 
methods were less apparent. Univariate approaches based on the linear model performed slightly 
better than multivariate approaches with small sample sizes. As the sample size increased, 
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results approximated those observed in the continuous case, where sparse multivariate methods 
such as SPLSDA outperformed the other approaches (Figure 3).  
 
An equally important aspect of a statistical procedure is the identification of important metabolites 
via variable selection or significance testing. Variable selection is not generally possible with PCR 
and random forest analyses, precluding assessment of these approaches for prioritizing individual 
metabolites. In either the continuous or binary settings, univariate approaches performed worse 
as the number of study participants increased (Figure 2-3). While counterintuitive given that 
statistical performance in general is enhanced with sample size, due to the frequently correlated 
nature of metabolomics data, false positives increased greatly with univariate methods as non-
significant variables are identified due to their correlation with significant variables (Figure 2-3). 
This result contributed to poor positive predictive value and reduced specificity for any of these 
approaches, both of which are important concerns for clinically relevant biomarker discovery. 
Multivariate approaches, by contrast, do not suffer this same drawback as their performance 
improves as the sample size increases (Figure 2-3). In the case of a continuous outcome, both 
LASSO and SPLS methods performed remarkably well, with SPLS slightly outperforming LASSO 
in terms of positive predictive value, negative predictive value, and number of false positives. 
Again, binary outcomes differed from statistical analysis of continuous outcomes, due to different 
performance for the respective estimators at different sample sizes. In small sample sizes, 
univariate procedures with a multiplicity correction had the best positive predictive value among 
all estimators (Figure 3). As the sample size increased to 1000 or 5000, the multivariate 
approaches again outperformed the univariate procedures as both LASSO and SPLSDA obtained 
the highest positive predictive value, negative predictive value, and the fewest number of false 
positives identified. Interestingly, for SPLSDA, the positive predictive value decreased from 
N=1000 to N=5000 as the number of false positives increased, although this was likely due to 
sensitivity of tuning parameter selection, which is required for the application of sparse methods.  
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Although we aggregated over all 10 significant metabolites to calculate measures of method 
performance, differences in operating characteristics such as power likely correspond with smaller 
effect sizes. While most methods will identify associations with large magnitudes of effect, 
potentially important discrepancies can become apparent for associations with smaller effect 
sizes. Thus, we also examined variation in power across a range of effect sizes for different 
statistical approaches and these results were concordant with those of aggregated data (Figures 
S1-S2).  
 
We also constructed simulations that involved scenarios that included negative as well as positive 
between-metabolite correlations, in addition to pairs of highly inter-correlated metabolites 
representing molecular markers putatively derived from the same biological pathway. We 
observed that the results of these additional simulations were very similar to those produced by 
the primary simulations and reported herein (Figure S3-S6), suggesting that our overall findings 
from the simulated data are relatively consistent across variations in simulated data structure. 
Collectively, these findings suggest the value of multivariate approaches for identifying metabolite 
markers that are associated with clinical traits. 
 
Statistical Analyses of Experimentally Derived Metabolomics Data 
Although the above reported results put forth a statistical framework for considering analysis of 
clinical metabolomics based on analyses of simulated data, we sought to compare our findings 
with those using actual “real world” experimentally derived metabolomics data. For these 
analyses, we used a nontargeted metabolomics based panel of 1933 metabolites measured 
across 2895 individuals (see Methods). We restricted attention to the methods that would easily 
allow for individual variable (i.e. metabolite) importance selection in this dataset, which precluded 
random forests and PCR from entering into the analysis. Analyses using the 3 main statistical 
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approaches (FDR, LASSO, and SPLS) revealed overlap (Figure 4) for only a minority of the total 
detected associations between metabolites and either a continuous variable (age) or a binary 
variable (sex). We excluded from the Venn diagram the results from the Bonferroni correction, 
given it produces a subset of the same metabolites chosen using the less conservative FDR 
correction. We applied a false discovery rate of 0.1, which suggests that 10% of the metabolites 
on average should be false discoveries. For both outcomes, use of the FDR resulted in a large 
number of statistically significant results with >50% of all assayed metabolites (1281/1933 for age, 
1312/1933 for sex) reaching threshold, suggesting that an FDR correction of 0.1 was in fact 
detecting nearly all of the signals. The approaches rooted in sparsity, however, obtained solutions 
with far fewer metabolite “hits”. In both cases, the LASSO analysis resulted in far fewer 
metabolites than an FDR correction (206 for sex, and 378 for age). By contrast, SPLS provides a 
solution with far fewer metabolite hits than either LASSO or an FDR correction (93 for sex, and 
37 for age). In the case of both age and sex, SPLS did not identify any new metabolites beyond 
those found in the LASSO or FDR subsets. We found in this study that when implementing cross 
validation to estimate tuning parameters of SPLS and SPLSDA, the cross validation curve is 
relatively flat, a previously encountered issue.[8] This suggests that different levels of sparsity 
were equally supported by the data, and we chose to use the most sparse option to identify the 
most important metabolites. SPLS is a relatively new approach for which these issues have not 
been well addressed, and this differs for the LASSO approach wherein estimating the tuning 
parameter is straighforward using glmnet in R.[24]  We repeated all analyses in the Framingham 
Heart Study dataset while including an indicator variable for specimen batch in all models. As 
shown in Figures S7, results of these analyses were similar to those in the original analyses 
 
To provide further context for these results, we used a basic network analysis to visualize 
correlations between metabolite measures in the Framingham cohort and compared the relative 
location of metabolites identified in association with age or sex by the univariate and multivariate 
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methods evaluated (Figure 5). We observed that univariate approaches tend to identify highly 
inter-correlated metabolites, whereas multivariate approaches exhibit a more parsimonious as 
well as broader selection of metabolites.  
 
Results from Both Simulated and Experimentally Derived Data 
The multiple statistical analysis approaches, when applied to both the simulated and the 
experimentally derived data, produced relatively comparable results with respect to very large 
numbers of metabolite markers identified by univariate compared to multivariate methods. Of the 
multivariate methods evaluated, the LASSO approach appeared to perform slightly better than 
the SPLS approach across the different types of simulated data structures and especially those 
involving larger numbers of metabolites (Figures 2-3). In comparison, the SPLS approach 
appeared to be more selective when applied to the experimentally derived data set (Figure 4). 
Given that selectivity alone is not necessarily a measure of true association, these results together 
suggest that results of either SPLS or LASSO would be reasonable to consider in a clinical study, 
particularly given that the metabolites selected by SPLS were identified in association with either 
the continuous or binary outcomes overlapped with those identified by the univariate or alternate 
multivariate methods.  
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DISCUSSION 
 
Through an extensive simulation study, we investigated the relative merits of traditional statistical 
and statistical learning approaches for the analysis of human metabolite data. Using a data 
structure based on real-world metabolite data with varying sample size, metabolite number, and 
outcome measures, our results offer a framework for considering optimal statistical approaches 
for a given study. We found that penalized approaches favoring sparsity led to substantially 
improved inference for a wide range of scenarios. Both the LASSO and SPLS (SPLSDA for binary 
outcomes) procedures provided reasonable results in all simulation scenarios studied, identifying 
important metabolites without suffering from large numbers of false positives. The only scenario 
wherein univariate procedures would be most reliable was when the sample size was small and 
the outcome was binary. With a binary outcome, there is relatively little information available to 
identify associations among a very large number of metabolites; thus, approaches that attempt to 
model all metabolites at once do not perform as well with smaller sample sizes. Interestingly, we 
observed the counterintuitive phenomenon that univariate procedures perform worse at 
identifying significant metabolites as the sample size grows. This appeared due to the correlation 
structure present in the data, which leads to a large number of false positives, and presents a 
finding with important implications for future analyses of nontargeted metabolomics data. 
 
Much of the current human metabolomics literature has relied on univariate approaches with a 
Bonferroni or FDR correction procedure, PCA, or PLSDA without penalization, in the absence of 
any formal evaluation of optimal statistical methods. While such approaches have proved useful 
in some respects for analyzing metabolite data, our findings indicate that these approaches may 
suffer major drawbacks in certain situations. Univariate approaches as discussed above can lead 
to misleading results when the data are inter-correlated, as is nearly always the case in 
metabolomics studies given common biochemical and biological origins. Other approaches such 
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as PCA or PCR do not provide measures of statistical significance, and only provide ad-hoc 
measures of variable importance. While metabolomics data may offer some unique challenges, 
including scale in metabolite levels and missingness across a population, as well as biologically 
driven inter-correlations, related molecular phenomics fields have similarly suggested that newer 
statistical approaches may be of great value in identifying statistical significance and prioritization 
of variables for biological follow up.[13,25-29] Our results suggest that approaches relying on 
sparsity to perform variable selection lead to quite good performance with respect to all the metrics 
examined and represent a path forward for future analyses. In particular, when the number of 
metabolites was similar to or exceeded the number of study subjects, sparse multivariate models 
exhibited robust statistical power with consistent results as expected given the design of methods 
that prioritize sparsity. Thus, nontargeted metabolomics analyses of relatively small sized cohorts 
are most likely to benefit from using sparse multivariate models in attempts to identify metabolites 
associated with a given outcome. 
  
There is in metabolomics a strong interest in pathway analyses that might offer some insights 
regarding the biological mechanisms underlying statistical associations observed between 
metabolites and a given outcome. These approaches remain in development, given ongoing 
challenges related to compound identification and limited knowledge regarding putative biological 
pathways relevant to novel metabolites.[30] Thus, we elected to use a relatively basic network 
analysis to visualize inter-metabolite associations and further examine our main findings in this 
context. We found that univariate approaches tend to identify highly inter-correlated metabolites, 
whereas multivariate approaches exhibit a more parsimonious as well as broader selection of 
metabolites. In effect, these findings also support the notion that multivariate compared to 
univariate approaches tend to select metabolites representing putative distinct and likely more 
orthogonal biological pathways of potential importance and interest in relation to a given outcome. 
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In our study, we found that multivariate approaches that assume some level of sparsity by design 
(i.e. some metabolites have a very small effect on the outcome) perform with the greatest 
efficiency for identifying important metabolites. Importantly, this conclusion is based on settings 
in which the relationship between a metabolite and outcome is linear. In the setting of nonlinearity, 
it is likely that random forest or other machine learning based approaches that allow for highly 
nonlinear relationships may be preferable, although this would require more formal evaluation 
than provided herein. The value of sparse multivariate analysis may be due to several potential 
reasons, including the large amount of correlation between metabolites that requires approaches 
to examine a metabolite conditional on the other metabolites. In addition, the fact that many 
metabolites indeed have little to no association with an outcome of interest favors approaches 
that enforce sparsity. With these results in mind, we can provide recommendations for future 
analysis of high dimensional metabolite data. For larger (>1000) sample sizes, multivariate 
approaches based on sparsity provide a very reasonable strategy to identifying important 
metabolites. In small sample sizes (<200), particularly for binary outcomes, there is no clear cut 
‘best’ method and the merits of each method will depend heavily on the structure of the data. In 
these cases, utilizing more than one analysis tool in conjunction could help identify key covariates. 
Importantly, the goal of the study should be taken into account before selecting a statistical 
approach. If hypothesis generating discovery of potentially important metabolites is of the utmost 
importance, and there is little penalty for false positives, then one can use all the proposed 
analyses, even those methods that tend to produce a large number of false positive results. If, 
however, false positives are very undesirable, then we recommend approaches such as LASSO 
or SPLS that impose sparsity into the model and tend to eliminate presumably less relevant 
metabolites.  
 
Our findings can be used to guide the design of future studies, particularly those for which 
investigators may be interested in estimating a minimum amount of statistical power to detect an 
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association of interest. If pre-existing knowledge of the distribution of metabolite values and their 
correlation structure is available, either through preliminary or previously analyzed data, then 
simulation studies similar to those described in this manuscript could be performed. Investigators 
can use an observed correlation structure to simulate a dataset of metabolite measures and then 
simulate outcomes given a known range of effect sizes, from which power to detect these effects 
can be estimated for different statistical approaches. 
 
There are several limitations of the study that merit consideration. The primary findings were 
based on simulated data, albeit data constructed based on the known structure of an existing 
high-dimensional data set derived from actual values in a human cohort. As such, our results may 
have been influenced by the nature of the underlying artificially created data structure. For this 
reason, we conducted parallel analyses in a de novo real-world dataset of metabolomics 
measures performed in a community-based cohort, and observed results that were largely 
consistent with those of the simulated data analyses. The observed substantial difference in 
performance between traditional statistical and statistical learning methods may well have 
emerged from the difference between univariate and multivariate methods. Accordingly, 
investigators have suggested that in situations where intercorrelations among predictor variables 
are expected, a permutation-based FDR approach to univariate analyses should be 
considered.[31] The extent to which FDR with permutation, or similar variants of univariate 
analyses, could effectively accommodate correlations and produce different results remains 
unclear and a subject of ongoing research.[32] It also should be emphasized that validity of results 
produced by any statistical model depends not only on model characteristics but also on data 
quality, which relies on mass spectrometry methods for correctly and consistently identifying 
metabolites from typical background artefact.[33] Thus, all statistical analyses are at risk for 
results of association analyses to be biased to the null due to technical mis-interpretations of noise 
for signal. It is important to note that this manuscript is focused on evaluating statistical 
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approaches aimed at identifying metabolites with potential true associations with a given outcome, 
based on the goal of discovering possible underlying mechanisms. By contrast, another distinct 
goal in clinical metabolomics research is to identify metabolites most important for the purpose of 
predicting a given outcome; to this end, univariate approaches may be equivalent or superior to 
multivariate approaches and this is an area that warrants future investigation. 
 
In summary, our findings further indicate that statistical learning approaches aimed at modeling a 
high-dimensional set of metabolites and their associations with a given outcome warrant more 
attention in the literature. Taken together, our results suggest that metabolomic analyses should 
shift towards use of multivariate approaches for identifying distinct markers associated with 
clinical traits. Univariate approaches, while simple to use, will identify large numbers of false 
positives when the metabolites are highly correlated with each other – a problem ubiquitous in 
metabolomics research. If interest lies solely in finding large, biologic pathways instead of causal 
markers (i.e. hypothesis-generating analyses), then univariate approaches may still be useful.  
When compared to traditional and frequently employed univariate approaches, statistical learning 
methods (such as LASSO or SPLS) offer effective and easy to implement options for handling 
high-dimensional, correlated data of the nature that is commonly seen in metabolomics. In fact, 
these approaches may well outperform many of the conventionally used methods across a wide 
variety of scenarios encountered in human metabolomics studies.  
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CONCLUSIONS 
 
We examined the results of applying both traditional statistical and statistical learning methods 
across a range of metabolomics datasets. We observed that when the number of metabolites was 
similar to or exceeded the number of study subjects, as is common with nontargeted 
metabolomics performed in small sized cohorts, sparse multivariate models demonstrated the 
most consistent results and the most statistical power. These findings have important implications 
for the analysis of metabolomics studies of human disease. 
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LIST OF ABBREVIATIONS 
 
FDR: false discovery rate 
LC-MS: liquid chromatography mass spectrometry 
LASSO: least absolute shrinkage and selection operator 
NPV: negative predictive value 
PCR: principal component regression 
PLS: partial least squares 
PLSA: partial least squares discriminant analysis 
PPV: positive predictive value 
SPLS: sparse partial least squares 
SPLSDA: sparse partial least squares discriminant analysis 
UPLC: ultra performance liquid chromatrography 
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Table 1. Data Structures Used for Analyses. 
 
 
 
Dataset Outcome 
Characteristics 
No. of 
Metabolites 
No. Observations 
(i.e. No. Persons) 
1 Continuous 200 200 
2 Continuous 200 1000 
3 Continuous 200 5000  
4 Continuous 2000 200 
5 Continuous 2000 1000 
6 Continuous 2000 5000  
7 Binary: 20% frequency 200 200 
8 Binary: 50% frequency 200 1000 
9 Binary: 50% frequency 200 5000  
10 Binary: 20% frequency 2000 200 
11 Binary: 50% frequency 2000 1000 
12 Binary: 50% frequency 2000 5000  
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Figure 1. Structure of the simulated dataset. To perform statistical analyses within a controlled 
environment with pre-specified metabolite-outcome associations, we created a simulated dataset 
based generally on data features observed in multiple real-world datasets. One such simulated 
dataset demonstrates a scenario with multiple clusters of metabolites that have within-cluster 
correlation but little cross-cluster, mimicking the inter-relationships observed in actual 
experimentally derived human metabolomics studies.  
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Figure 2. Results for a continuous outcome. The sensitivity, specificity, positive predictive 
value (PPV), negative predictive value (PPV), and false positive rate are displayed (as percent 
color fill of each bar) for each statistical method, reflecting their ability to correctly identify the top 
ten simulated metabolite associations, across varying numbers of total metabolite measures 
(M=200, or M=2000) in study samples collected from varying numbers of study subjects (N=200, 
N=1000, or N=5000). PCR, principal components regression; BON, Bonferroni; FDR, false 
discovery rate; LASSO, lease absolute shrinkage and selection operator; SPLS, sparse partial 
least squares; RF, random forests. 
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Figure 3. Results for a binary outcome. The sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (PPV), and false positive rate are displayed (as percent color 
fill of each bar) for each statistical method, reflecting their ability to correctly identify the top ten 
simulated metabolite associations, across varying numbers of total metabolite measures 
(M=200, or M=2000) in study samples collected from varying numbers of study subjects 
(N=200, N=1000, or N=5000). PCR, principal components regression; BON, Bonferroni; FDR, 
false discovery rate; LASSO, lease absolute shrinkage and selection operator; SPLS, sparse 
partial least squares; RF, random forests. 
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Figure 4. Analysis of actual, experimentally derived metabolomics data. The number of metabolites found in association with age 
(continuous outcome) and sex (binary outcome) from experimentally derived metabolomics studies (see text) for different statistical 
methods applied: false discovery rate (FDR), sparse partial least squares (SPLS), and least absolute shrinkage and selection operator 
(LASSO). The number of metabolite correlates found in common by the different methods is relatively small compared to the total 
number of apparently significantly associated metabolites. 
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Figure 5. Putative network distribution of metabolites identified by different methods used to analyze cohort-based 
metabolomics data. The number of metabolites found in association with age (continuous outcome) and sex (binary outcome) from 
experimentally derived metabolomics studies (see text) for the different statistical methods applied was greater for traditional than for 
statistical learning models. Notably, the former identified metabolites that tended to be highly correlated with each other (Spearman 
rho ≥0.65), whereas the latter identified a more parsimonious number of metabolites distributed across the putative network of all 
highly inter-correlated metabolites. BON, Bonferroni; FDR, false discovery rate; LASSO, lease absolute shrinkage and selection 
operator; SPLS, sparse partial least squares. 
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Table S1. Known Metabolite Compounds Assayed by the LC-MS Method Used 
 
Metabolite Type Mass-to-Charge Ratio ID 
polar molecule  227.0645 DEOXYURIDINE 
free fatty acid 227.2012 Myristic Acid 
polar molecule  241.0738 LUMICHROME 
free fatty acid 241.2170 Pentadecanoic Acid 
polar molecule  242.0801 CYTIDINE 
free fatty acid 253.2172 Palmitoleic Acid 
free fatty acid 255.2329 Palmitic Acid 
eicosanoid 265.1812 tetranor 12(R) HETE 
polar molecule  267.0475 HOMOCYSTINE 
free fatty acid 267.2330 Heptadecaenoic Acid 
steroid 269.1758 Estrone 
free fatty acid 275.2020 Stearidonic Acid 
free fatty acid 277.2175 GAMMA-LINOLENATE 
free fatty acid 279.2331 LINOLEATE 
free fatty acid 281.2489 ELAIDATE 
eicosanoid 291.1967 13S-HpOTrE(gamma) 
eicosanoid 293.2122 13-oxoODE 
eicosanoid 293.2122 9-oxoODE 
eicosanoid 295.2275 9-HODE 
eicosanoid 299.2010 15-oxoETE 
eicosanoid 299.2039 5-oxoETE 
free fatty acid 301.2172 Eicosapentaenoic Acid 
free fatty acid 303.2331 Arachidonic Acid 
free fatty acid 305.2486 Eicosatrienoic Acid 
free fatty acid 307.2644 Eicosadienoic Acid 
free fatty acid 309.2044 MYRISTATE 
free fatty acid 309.2798 Gondolic Acid 
free fatty acid 311.2955 ARACHIDATE 
free fatty acid 313.2387 PALMITOLEATE 
	 2 
eicosanoid 315.1951 15-keto-PGA1 
eicosanoid 315.1964 13(S) HOTrE(y) 
eicosanoid 315.1971 bicyclo PGE2 
eicosanoid 315.2000 5S-HpEPE 
eicosanoid 315.2000 15d PGJ2 
eicosanoid 317.2110 HXA3 
eicosanoid 317.2115 5(S) HEPE 
eicosanoid 317.2117 18(S) HEPE 
eicosanoid 317.2118 15(S) HEPE 
eicosanoid 317.2121 14(15) EpETE 
eicosanoid 317.2128 12epi LTB4 
eicosanoid 317.2136 5,15-diHETE 
eicosanoid 319.2260 16-HETE 
eicosanoid 319.2278 11-HETE 
eicosanoid 319.2283 14,15-EET 
eicosanoid 319.2291 5,6-EET 
eicosanoid 321.1712 11-dehydro-2,3-dinor-TXB2 
eicosanoid 321.2423 8(S) HETrE 
eicosanoid 321.2435 15(S) HETrE 
polar molecule  323.0974 CELLOBIOSE 
endocannabinoid 326.3038 Stearoyl EA 
free fatty acid 327.2326 Docosahexaenoic Acid 
polar molecule  329.0161 DEOXYURIDINE-MONOPHOSPHATE 
eicosanoid 331.1890 9S-HpOTrE 
steroid 331.1909 Estradiol 
eicosanoid 331.1916 PGD3 
eicosanoid 333.2061 8-iso-15-keto-PGF2alpha 
eicosanoid 333.2064 PGA2 
eicosanoid 333.2070 12oxo LTB4 
eicosanoid 333.2070 dhk PGE2 
eicosanoid 333.2071 13,14-dihydro-15-keto-PGA2 
eicosanoid 333.2072 ent-PGE2 
eicosanoid 333.2074 LXB4 
eicosanoid 333.2077 20cooh AA 
	 3 
eicosanoid 333.2080 8-iso-PGA2 
free fatty acid 333.2811 Docosatrienoic Acid 
eicosanoid 335.2222 15S-HpETE 
eicosanoid 335.2226 PGF2beta 
eicosanoid 335.2228 8,12-iso-iPF2Ã -VI-1,5-lactone 
eicosanoid 335.2228 14,15-DiHETE 
eicosanoid 335.2228 8-iso-PGA1 
eicosanoid 335.2232 15R-PGE1 
eicosanoid 335.2234 15R-PGF2alpha 
eicosanoid 335.2249 5,6-diHETE 
free fatty acid 335.2959 Docosadienoic Acid 
free fatty acid 337.3116 ERUCATE 
eicosanoid 339.2175 12-HHTrE 
free fatty acid 339.2533 Linoleic Acid 
free fatty acid 339.3269 Behenic Acid 
eicosanoid 341.2163 17S-HpDHA 
free fatty acid 343.2853 Stearic Acid 
eicosanoid 351.2170 9-oxoOTrE 
eicosanoid 351.2202 8-iso-PGE2 
free fatty acid 351.3270 Tricosenoic Acid 
eicosanoid 353.2319 13(S) HOTrE 
eicosanoid 353.2337 9(S) HOTrE 
eicosanoid 353.2343 11b dhk PGF2a 
free fatty acid 353.3427 TRICOSANOATE 
eicosanoid 355.2486 13-HODE 
eicosanoid 355.2486 12,13 EpOME 
endocannabinoid 358.2962 Palmitoyl Ethanolamide  
endocannabinoid 358.2966 Palmitoyl EA or  
steroid 359.1867 Cortisone 
eicosanoid 359.2222 5,6-diHETrE 
free fatty acid 359.2971 Docosaenoic Acid 
eicosanoid 363.2556 1a,1b-dihomo-PGE1 
eicosanoid 363.2557 dihomo PGF2a 
polar molecule  364.0595 CYTIDINE 2',3'-CYCLIC PHOSPHATE 
	 4 
free fatty acid 365.2658 STEARATE 
free fatty acid 367.3583 Lignoceric Acid 
bile acid 375.2906 Lithocholic Acid 
eicosanoid 379.2486 15-HETE 
endocannabinoid 382.2975 Linoleoyl EA 
endocannabinoid 384.3114 Oleoyl Ethanolamide  
endocannabinoid 384.3128 Oleoyl EA 
free fatty acid 387.3286 Nervonic Acid 
steroid 389.2309 11-deoxycortisosterone  
or 17a-hydroxyprogesterone 
bile acid 389.2697 Cholic Acid 
free fatty acid 391.2850 Adrenic Acid 
bile acid 391.2862 Deoxycholic Acid 
bile acid 391.2863 Ursodeoxycholic acid 
eicosanoid 393.2280 15d PGD2 
eicosanoid 393.2294 PGB2 
eicosanoid 395.2429 LTB4 
eicosanoid 395.2433 15-epi-PGA1 
eicosanoid 395.2442 PGA1 
eicosanoid 395.2445 12,13 diHOME 
polar molecule  397.3365 ERUCATE 
polar molecule  401.1297 PALATINOSE 
eicosanoid 403.2485 15 oxoEDE 
eicosanoid 403.2500 14 HDoHE 
steroid 405.2265 Unk 
steroid 405.2271 Unk 
steroid 405.2277 11-deoxycortisol 
steroid 405.2287 Unk 
steroid 405.2295 CORTEXOLONE 
polar molecule  407.0623 INOSINE MONOPHOSPHATE 
bile acid 407.2804 b-Muricholic Acid 
eicosanoid 411.2365 6S-LXA4 
endocannabinoid 415.3076 OLEOYL-GLYCEROL 
eicosanoid 417.2246 12S-HpETE 
	 5 
eicosanoid 417.2284 8,15-diHETE 
steroid 419.2078 CORTISONE 
steroid 421.2239 CORTISOL 
steroid 421.2241 Cortisol 
endocannabinoid 423.3101 2-AG ether 
steroid 425.2547 allo-Tetrahydrocortisol 
free fatty acid 425.3617 NERVONATE 
bile acid 430.2965 Glycodeoxycholic Acid 
endocannabinoid 430.3028 Docosahexanoyl EA 
bile acid 435.3122 LITHOCHOLATE 
endocannabinoid 437.2899 2-AG maybe 
bile acid 448.3074 Glycoursodeoxycholic Acid 
eicosanoid 451.2348 6k PGF1a 
bile acid 451.3071 Chenodeoxycholic acid 
bile acid 464.3021 GLYCOCHOLATE 
bile acid 470.2848 Glycochenodeoxycholic Acid 
bile acid 480.2745 Tauroursodeoxycholic acid 
eicosanoid 495.2607 14,15 LTD4 
bile acid 498.2904 Taurodeoxycholic Acid 
bile acid 514.2843 Taurocholic Acid 
bile acid 520.2656 Taurochenodeoxycholic acid 
polar molecule  540.0464 ADENOSINE DIPHOSPHATE RIBOSE 
polar molecule  610.0507 ADP-GLUCOSE 
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Figure S1. Estimates of power to detect metabolites associated with a continuous outcome 
for a given effect size based on simulations. The estimated power to detect the top ten 
metabolite associations per effect size is shown for each statistical method, across varying 
numbers of total metabolite measures (M=200, or M=2000) in study samples collected from 
varying numbers of study subjects (N=200, N=1000, or N=5000). BON, Bonferroni; FDR, false 
discovery rate; LASSO, lease absolute shrinkage and selection operator; SPLS, sparse partial 
least squares. 
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Figure S2. Estimates of power to detect metabolites associated with a binary outcome for 
a given effect size based on simulations. The estimated power to detect the top ten metabolite 
associations per effect size is shown for each statistical method, across varying numbers of total 
metabolite measures (M=200, or M=2000) in study samples collected from varying numbers of 
study subjects (N=200, N=1000, or N=5000). BON, Bonferroni; FDR, false discovery rate; 
LASSO, lease absolute shrinkage and selection operator; SPLS, sparse partial least squares. 
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Figure S3. Results for a continuous outcome based on simulations with positive and 
negative inter-metabolite correlations. The sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (PPV), and false positive rate are displayed (as percent color fill 
of each bar) for each statistical method, reflecting their ability to correctly identify the top ten 
simulated metabolite associations, across varying numbers of total metabolite measures (M=200, 
or M=2000) in study samples collected from varying numbers of study subjects (N=200, N=1000, 
or N=5000). PCR, principal components regression; BON, Bonferroni; FDR, false discovery rate; 
LASSO, lease absolute shrinkage and selection operator; SPLS, sparse partial least squares; RF, 
random forests. 
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Figure S4. Results for a binary outcome based on simulations with positive and negative 
inter-metabolite correlations. The sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (PPV), and false positive rate are displayed (as percent color fill of each 
bar) for each statistical method, reflecting their ability to correctly identify the top ten simulated 
metabolite associations, across varying numbers of total metabolite measures (M=200, or 
M=2000) in study samples collected from varying numbers of study subjects (N=200, N=1000, or 
N=5000). PCR, principal components regression; BON, Bonferroni; FDR, false discovery rate; 
LASSO, lease absolute shrinkage and selection operator; SPLS, sparse partial least squares; RF, 
random forests. 
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	 10 
Figure S5. Results for a continuous outcome based on simulations with highly correlated 
important covariates. The sensitivity, specificity, positive predictive value (PPV), negative 
predictive value (PPV), and false positive rate are displayed (as percent color fill of each bar) for 
each statistical method, reflecting their ability to correctly identify the top ten simulated metabolite 
associations, across varying numbers of total metabolite measures (M=200, or M=2000) in study 
samples collected from varying numbers of study subjects (N=200, N=1000, or N=5000). PCR, 
principal components regression; BON, Bonferroni; FDR, false discovery rate; LASSO, lease 
absolute shrinkage and selection operator; SPLS, sparse partial least squares; RF, random 
forests. 
 
                                     Statistical Method 
Pa
ra
m
et
er
 o
f M
et
ho
d 
Pe
rf
or
m
an
ce
 
 
 
 
 
 
  
N = 5000
N = 1000
N = 200
N = 5000
N = 1000
N = 200
N = 5000
N = 1000
N = 200
N = 5000
N = 1000
N = 200
N = 5000
N = 1000
N = 200
N = 5000
N = 1000
N = 200
PC
R
BO
N
FD
R
LA
SS
O
SP
LS
RF PC
R
BO
N
FD
R
LA
SS
O
SP
LS
RF
Sens
Spec
PPV
NPV
False Pos
Top 10
M = 200 M = 2000
	 11 
Figure S6. Results for a binary outcome based on simulations with highly correlated 
important covariates. The sensitivity, specificity, positive predictive value (PPV), negative 
predictive value (PPV), and false positive rate are displayed (as percent color fill of each bar) for 
each statistical method, reflecting their ability to correctly identify the top ten simulated metabolite 
associations, across varying numbers of total metabolite measures (M=200, or M=2000) in study 
samples collected from varying numbers of study subjects (N=200, N=1000, or N=5000). PCR, 
principal components regression; BON, Bonferroni; FDR, false discovery rate; LASSO, lease 
absolute shrinkage and selection operator; SPLS, sparse partial least squares; RF, random 
forests. 
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Figure S7. Results of analyzing actual, experimentally derived metabolomics data while controlling for batch effects. The 
number of metabolites found in association with age (continuous outcome) and sex (binary outcome) from experimentally derived 
metabolomics studies (see text) for different statistical methods applied: false discovery rate (FDR), sparse partial least squares 
(SPLS), and least absolute shrinkage and selection operator (LASSO). The number of metabolite correlates found in common by the 
different methods is relatively small compared to the total number of apparently significantly associated metabolites. 
 
 
 
 
 
